Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Podobne zapisy

• Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
  od: Nattinger, Ann Butler, i wsp.
  Wydane: (2015)
• Temporal Trends and Regional Variation in the Utilization of Low-Value Breast Cancer Care: Has the Choosing Wisely Campaign Made a Difference?
  od: Neuner, Joan, i wsp.
  Wydane: (2019)
• The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees
  od: Neuner, Joan M., i wsp.
  Wydane: (2015)
• Socioeconomic Disparities in Mortality Among Women With Incident Breast Cancer Before and After Implementation of Medicare Part D
  od: Nattinger, Ann B., i wsp.
  Wydane: (2017)
• Re-examining the Relationship of Breast Cancer Hospital and Surgical Volume to Mortality: An Instrumental Variable Analysis
  od: Pezzin, Liliana E., i wsp.
  Wydane: (2015)